Genelux prices $20.0 million public offering of 6,666,667 shares at $3.00 each
Genelux Corporation agreed on January 8, 2026 to sell 6,666,667 new shares of common stock at $3.00 per share through an underwritten offering led by Lucid Capital Markets, expected to bring in about $20.0 million gross before underwriting discounts and expenses. The company says net proceeds will go to general corporate purposes, including research and development and clinical trial costs, and the new shares will dilute existing holders' ownership.
Key points
- Offering of 6,666,667 shares at $3.00 per share, with gross proceeds of about $20.0 million before discounts and expenses
- Underwriter has a 30-day option to buy up to 1,000,000 additional shares at the offering price
- Closing is expected on or about January 9, 2026, subject to customary closing conditions
- Proceeds are expected to fund general corporate purposes, including research and development and clinical trial expenses
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.